Linezolid for the treatment of drug-resistant tuberculosis in children: A review and recommendations

Tuberculosis

Volumn 94, Issue 2, 2014, Pages 93-104

  Garcia Prats, Anthony J ^a   Rose, Penelope C ^a   Hesseling, Anneke C ^a   Schaaf, H Simon ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

children; Linezolid; MDR TB; Tuberculosis; XDR TB

Indexed keywords

ACETAMIDE DERIVATIVE; LINEZOLID; OXAZOLIDINONE DERIVATIVE; TUBERCULOSTATIC AGENT;

CHILD; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG MONITORING; HUMAN; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ACETAMIDES; ANTITUBERCULAR AGENTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMANS; OXAZOLIDINONES; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84893907642     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2013.10.003     Document Type: Review

References (111)

1. L.J. Nelson, and C.D. Wells Global epidemiology of childhood tuberculosis Int J Tuberc Lung Dis 8 2004 636 647
2. World Health Organization Global tuberculosis report 2012 2012 WHO Geneva, Switzerland
3. D. Ettehad, H.S. Schaaf, J.A. Seddon, G.S. Cooke, and N. Ford Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis Lancet Infect Dis 12 2012 449 456
4. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control Wkly Epidemiol Rec 81 2006 430 432
5. K.R. Jacobson, D.B. Tierney, C.Y. Jeon, C.D. Mitnick, and M.B. Murray Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis Clin Infect Dis 51 2010 6 14
6. World Health Organization Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008 2008
7. W.J. Burman, M.F. Cotton, D.M. Gibb, A.S. Walker, A.A. Vernon, and P.R. Donald Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens PLoS Med 5 2008 e176
8. P.R. Donald, A. Ahmed, W.J. Burman, M.F. Cotton, S.M. Graham, C. Mendel, H. McIlleron, W.R. Mac Kenzie, S. Nachman, H.S. Schaaf, J.R. Starke, C. Wingfield, and A.C. Hesseling Requirements for the clinical evaluation of new anti-tuberculosis agents in children Int J Tuberculosis Lung Dis 17 2013 794 799
9. P.R. Donald The assessment of new anti-tuberculosis drugs for a paediatric indication Int J Tuberc Lung Dis 11 2007 1162 1165
10. S. Thee, A.A. Detjen, U. Wahn, and K. Magdorf Isoniazid pharmacokinetic studies of the 1960s: considering a higher isoniazid dose in childhood tuberculosis Scand J Infect Dis 42 2010 294 298
11. S. Thee, J.A. Seddon, P.R. Donald, H.I. Seifart, C.J. Werely, A.C. Hesseling, B. Rosenkranz, S. Roll, K. Magdorf, and H.S. Schaaf Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations Antimicrob Agents Chemother 55 2011 5560 5567
12. P.R. Donald, J.S. Maritz, and A.H. Diacon The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children Tuberculosis (Edinb) 91 2011 196 207
13. G.L. Kearns, S.M. Abdel-Rahman, S.W. Alander, D.L. Blowey, J.S. Leeder, and R.E. Kauffman Developmental pharmacology - drug disposition, action, and therapy in infants and children New Engl J Med 349 2003 1157 1167
14. D.R. Butler, R.J. Kuhn, and M.H. Chandler Pharmacokinetics of anti-infective agents in paediatric patients Clin Pharmacokinet 26 1994 374 395
15. D.J. Diekema, and R.N. Jones Oxazolidinone antibiotics The Lancet 358 2001 1975 1982
16. D.L. Shinabarger, K.R. Marotti, R.W. Murray, A.H. Lin, E.P. Melchior, S.M. Swaney, D.S. Dunyak, W.F. Demyan, and J.M. Buysse Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions Antimicrob Agents Chemother 41 1997 2132 2136
17. A.H. Lin, R.W. Murray, T.J. Vidmar, and K.R. Marotti The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin Antimicrob Agents Chemother 41 1997 2127 2131
18. The MSF Access Campaign, and The International Union Against Tuberculosis and Lung Disease DR-TB drugs under the microscope: sources and prices for drug-resistant tuberculosis medicines 2nd ed. November 2012
19. J.C. Rodriguez, M. Ruiz, M. Lopez, and G. Royo In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis Int J Antimicrob Agents 20 2002 464 467
20. G.E. Zurenko, B.H. Yagi, R.D. Schaadt, J.W. Allison, J.O. Kilburn, S.E. Glickman, D.K. Hutchinson, M.R. Barbachyn, and S.J. Brickner In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents Antimicrob Agents Chemother 40 1996 839 845
21. L. Alcala, M.J. Ruiz-Serrano, C. Perez-Fernandez Turegano, D. Garcia De Viedma, M. Diaz-Infantes, M. Marin-Arriaza, and E. Bouza In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs Antimicrob Agents Chemother 47 2003 416 417
22. Z. Erturan, and M. Uzun In vitro activity of linezolid against multidrug-resistant Mycobacterium tuberculosis isolates Int J Antimicrob Agents 26 2005 78 80
23. R. Sood, M. Rao, S. Singhal, and A. Rattan Activity of RBx 7644 and RBx 8700, new investigational oxazolidinones, against Mycobacterium tuberculosis infected murine macrophages Int J Antimicrob Agents 25 2005 464 468
24. M. Tato, E.G. de la Pedrosa, R. Canton, I. Gomez-Garcia, J. Fortun, P. Martin-Davila, F. Baquero, and E. Gomez-Mampaso In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates Int J Antimicrob Agents 28 2006 75 78
25. S. Rusch-Gerdes, G.E. Pfyffer, M. Casal, M. Chadwick, and S. Siddiqi Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials J Clin Microbiol 44 2006 688 692
26. C. Yang, H. Lei, D. Wang, X. Meng, J. He, A. Tong, L. Zhu, Y. Jiang, and M. Dong In vitro activity of linezolid against clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains from Beijing, China Jpn J Infect Dis 65 2012 240 242
27. K. Angeby, P. Jureen, G. Kahlmeter, S.E. Hoffner, and T. Schon Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis Bull World Health Organ 90 2012 693 698
28. World Health Organization Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs 2008 WHO Geneva, Switzerland
29. World Health Organization prepared by Fuad Mirzayev Summary of outcomes from who expert group meeting on drug susceptibility testing - PRELIMINARY Fourth annual GLI meeting 17 April 2012 2012
30. T. Schon, P. Jureen, E. Chryssanthou, C.G. Giske, E. Sturegard, G. Kahlmeter, S. Hoffner, and K.A. Angeby Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis Int J Tuberc Lung Dis 15 2011 502 509
31. T.S. Huang, Y.C. Liu, C.L. Sy, Y.S. Chen, H.Z. Tu, and B.C. Chen In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years Antimicrob Agents Chemother 52 2008 2226 2227
32. T. Prammananan, A. Chaiprasert, and M. Leechawengwongs In vitro activity of linezolid against multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant (XDR)-TB isolates Int J Antimicrob Agents 33 2009 190 191
33. J.C. Rodriguez Diaz, M. Ruiz, M. Lopez, and G. Royo Synergic activity of fluoroquinolones and linezolid against Mycobacterium tuberculosis Int J Antimicrob Agents 21 2003 354 356
34. R. Cremades, J.C. Rodriguez, E. Garcia-Pachon, A. Galiana, M. Ruiz-Garcia, P. Lopez, and G. Royo Interaction between linezolid and Mycobacterium tuberculosis in an experimental in vitro model APMIS 119 2011 304 308
35. M.H. Cynamon, S.P. Klemens, C.A. Sharpe, and S. Chase Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model Antimicrob Agents Chemother 43 1999 1189 1191
36. K.N. Williams, C.K. Stover, T. Zhu, R. Tasneen, S. Tyagi, J.H. Grosset, and E. Nuermberger Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model Antimicrob Agents Chemother 53 2009 1314 1319
37. K.N. Williams, S.J. Brickner, C.K. Stover, T. Zhu, A. Ogden, R. Tasneen, S. Tyagi, J.H. Grosset, and E.L. Nuermberger Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis Am J Respir Crit Care Med 180 2009 371 376
38. L. Fattorini, D. Tan, E. Iona, M. Mattei, F. Giannoni, L. Brunori, S. Recchia, and G. Orefici Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice Antimicrob Agents Chemother 47 2003 360 362
39. R.S. Wallis, W. Jakubiec, V. Kumar, G. Bedarida, A. Silvia, D. Paige, T. Zhu, M. Mitton-Fry, L. Ladutko, S. Campbell, and P.F. Miller Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis Antimicrob Agents Chemother 55 2011 567 574
40. R. Dietze, D.J. Hadad, B. McGee, L.P. Molino, E.L. Maciel, C.A. Peloquin, D.F. Johnson, S.M. Debanne, K. Eisenach, W.H. Boom, M. Palaci, and J.L. Johnson Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis Am J Respir Crit Care Med 178 2008 1180 1185
41. J. Fortun, P. Martin-Davila, E. Navas, M.J. Perez-Elias, J. Cobo, M. Tato, E.G. De la Pedrosa, E. Gomez-Mampaso, and S. Moreno Linezolid for the treatment of multidrug-resistant tuberculosis J Antimicrob Chemother 56 2005 180 185
42. B. von der Lippe, P. Sandven, and O. Brubakk Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB) - a report of ten cases J Infect 52 2006 92 96
43. I.N. Park, S.B. Hong, Y.M. Oh, M.N. Kim, C.M. Lim, S.D. Lee, Y. Koh, W.S. Kim, D.S. Kim, W.D. Kim, and T.S. Shim Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis J Antimicrob Chemother 58 2006 701 704
44. W.J. Koh, O.J. Kwon, H. Gwak, J.W. Chung, S.N. Cho, W.S. Kim, and T.S. Shim Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis J Antimicrob Chemother 64 2009 388 391
45. W.W. Yew, C.H. Chau, and K.H. Wen Linezolid in the treatment of 'difficult' multidrug-resistant tuberculosis Int J Tuberc Lung Dis 12 2008 345 346
46. G.B. Migliori, B. Eker, M.D. Richardson, G. Sotgiu, J.P. Zellweger, A. Skrahina, J. Ortmann, E. Girardi, H. Hoffmann, G. Besozzi, N. Bevilacqua, D. Kirsten, R. Centis, and C. Lange A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis Eur Respir J 34 2009 387 393
47. H.S. Nam, W.J. Koh, O.J. Kwon, S.N. Cho, and T.S. Shim Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis Int J Antimicrob Agents 33 2009 92 93
48. Z.F. Udwadia, T. Sen, and G. Moharil Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective Eur Respir J 35 2010 936 938 author reply 938-940
49. H.A. Anger, F. Dworkin, S. Sharma, S.S. Munsiff, D.M. Nilsen, and S.D. Ahuja Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06 J Antimicrob Chemother 65 2010 775 783
50. G.F. Schecter, C. Scott, L. True, A. Raftery, J. Flood, and S. Mase Linezolid in the treatment of multidrug-resistant tuberculosis Clin Infect Dis 50 2010 49 55
51. S. De Lorenzo, R. Centis, L. D'Ambrosio, G. Sotgiu, and G.B. Migliori On linezolid efficacy and tolerability Eur Respir J 39 2012 770 772
52. R. Singla, J.A. Caminero, A. Jaiswal, N. Singla, S. Gupta, R.K. Bali, and D. Behera Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India Eur Respir J 39 2012 956 962
53. M. Villar, G. Sotgiu, L. D'Ambrosio, E. Raymundo, L. Fernandes, J. Barbedo, N. Diogo, C. Lange, R. Centis, and G.B. Migliori Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis Eur Respir J 38 2011 730 733
54. R. Condos, N. Hadgiangelis, E. Leibert, G. Jacquette, T. Harkin, and W.N. Rom Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis Chest 134 2008 187 192
55. S.J. Tangg, Q. Zhang, L.H. Zheng, H. Sun, J. Gu, X.H. Hao, Y.D. Liu, L. Yao, and H.P. Xiao Efficacy and safety of linezolid in the treatment of extensively drug-resistant tuberculosis Jpn J Infect Dis 64 2011 509 512
56. H.B. Xu, R.H. Jiang, L. Li, and H.P. Xiao Linezolid in the treatment of MDR-TB: a retrospective clinical study Int J Tuberc Lung Dis 16 2012 358 363
57. H. Cox, and N. Ford Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis Int J Tuberc Lung Dis 16 2012 447 454
58. G. Sotgiu, R. Centis, L. D'Ambrosio, J.W. Alffenaar, H.A. Anger, J.A. Caminero, P. Castiglia, S. De Lorenzo, G. Ferrara, W.J. Koh, G.F. Schecter, T.S. Shim, R. Singla, A. Skrahina, A. Spanevello, Z.F. Udwadia, M. Villar, E. Zampogna, J.P. Zellweger, A. Zumla, and G.B. Migliori Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis Eur Respir J 40 2012 1430 1442
59. M. Lee, J. Lee, M.W. Carroll, H. Choi, S. Min, T. Song, L.E. Via, L.C. Goldfeder, E. Kang, B. Jin, H. Park, H. Kwak, H. Kim, H.S. Jeon, I. Jeong, J.S. Joh, R.Y. Chen, K.N. Olivier, P.A. Shaw, D. Follmann, S.D. Song, J.K. Lee, D. Lee, C.T. Kim, V. Dartois, S.K. Park, S.N. Cho, and C.E. Barry III Linezolid for treatment of chronic extensively drug-resistant tuberculosis N Engl J Med 367 2012 1508 1518
60. J.C. Rodriguez, L. Cebrian, M. Lopez, M. Ruiz, I. Jimenez, and G. Royo Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis J Antimicrob Chemother 53 2004 441 444
61. S. Garazzino, and P.A. Tovo Clinical experience with linezolid in infants and children J Antimicrob Chemother 66 Suppl. 4 2011 iv23 iv41
62. H.S. Schaaf, M. Willemse, and P.R. Donald Long-term linezolid treatment in a young child with extensively drug-resistant tuberculosis Pediatr Infect Dis J 28 2009 748 750
63. P.C. Rose, U.M. Hallbauer, J.A. Seddon, A.C. Hesseling, and H.S. Schaaf Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children Int J Tuberc Lung Dis 16 2012 1588 1593
64. M. Pinon, C. Scolfaro, E. Bignamini, G. Cordola, I. Esposito, R. Milano, F. Mignone, C. Bertaina, and P.A. Tovo Two pediatric cases of multidrug-resistant tuberculosis treated with linezolid and moxifloxacin Pediatrics 126 2010 e1253 e1256
65. N. Dauby, I. Muylle, F. Mouchet, R. Sergysels, and M.C. Payen Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis Pediatr Infect Dis J 30 2011 812 813
66. P. Kjollerstrom, M.J. Brito, C. Gouveia, G. Ferreira, and L. Varandas Linezolid in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis in paediatric patients: experience of a paediatric infectious diseases unit Scand J Infect Dis 43 2011 556 559
67. A. Katragkou, C. Antachopoulos, E. Hatziagorou, M. Sdougka, E. Roilides, and J. Tsanakas Drug-resistant tuberculosis in two children in Greece: report of the first extensively drug-resistant case Eur J Pediatr 2012
68. A.S. De Vriese, R.V. Coster, J. Smet, S. Seneca, A. Lovering, L.L. Van Haute, L.J. Vanopdenbosch, J.J. Martin, C.C. Groote, S. Vandecasteele, and J.R. Boelaert Linezolid-induced inhibition of mitochondrial protein synthesis Clin Infect Dis 42 2006 1111 1117
69. D.C. Vinh, and E. Rubinstein Linezolid: a review of safety and tolerability J Infect 59 Suppl. 1 2009 S59 S74
70. E. Chiappini, C. Conti, L. Galli, and M. de Martino Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review Clin Ther 32 2010 66 88
71. L. Saiman, J. Goldfarb, S.A. Kaplan, K. Wible, B. Edge-Padbury, S. Naberhuis-Stehouwer, and J.B. Bruss Safety and tolerability of linezolid in children Pediatr Infect Dis J 22 2003 S193 S200
72. S.L. Gerson, S.L. Kaplan, J.B. Bruss, V. Le, F.M. Arellano, B. Hafkin, and D.J. Kuter Hematologic effects of linezolid: summary of clinical experience Antimicrob Agents Chemother 46 2002 2723 2726
73. B. Spellberg, T. Yoo, and A.S. Bayer Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6 J Antimicrob Chemother 54 2004 832 835
74. D. Plachouras, E. Giannitsioti, S. Athanassia, F. Kontopidou, A. Papadopoulos, K. Kanellakopoulou, and H. Giamarellou No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment Clin Infect Dis 43 2006 e89 e91
75. A. Soriano, M. Ortega, S. Garcia, G. Penarroja, A. Bove, M. Marcos, J.C. Martinez, J.A. Martinez, and J. Mensa Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid Antimicrob Agents Chemother 51 2007 2559 2563
76. H.C. Meissner, T. Townsend, W. Wenman, S.L. Kaplan, M.R. Morfin, B. Edge-Padbury, S. Naberhuis-Stehouwer, and J.B. Bruss Hematologic effects of linezolid in young children Pediatr Infect Dis J 22 2003 S186 S192
77. A.M. Bressler, S.M. Zimmer, J.L. Gilmore, and J. Somani Peripheral neuropathy associated with prolonged use of linezolid Lancet Infect Dis 4 2004 528 531
78. S. Nambiar, N. Rellosa, R.T. Wassel, V. Borders-Hemphill, and J.S. Bradley Linezolid-associated peripheral and optic neuropathy in children Pediatrics 127 2011 e1528 e1532
79. K. Brennan, B.L. Jones, and L. Jackson Auditory nerve neuropathy in a neonate after linezolid treatment Pediatr Infect Dis J 28 2009 169
80. J.J. van der Watt, T.B. Harrison, M. Benatar, and J.M. Heckmann Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: a systematic review Int J Tuberc Lung Dis 15 2011 722 728
81. S. Nair, W. Maguire, H. Baron, and R. Imbruce The effect of cycloserine on pyridoxine-dependent metabolism in tuberculosis J Clin Pharmacol 16 1976 439 443
82. J.S. Kass, and W.X. Shandera Nervous system effects of antituberculosis therapy CNS Drugs 24 2010 655 667
83. G. McComsey, and J.T. Lonergan Mitochondrial dysfunction: patient monitoring and toxicity management J Acquir Immune Defic Syndr 37 Suppl. 1 2004 S30 S35
84. M. Youle, and M. Osio A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl l-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection HIV Med 8 2007 241 250
85. R. Yogev, L.E. Patterson, S.L. Kaplan, S. Adler, M.R. Morfin, A. Martin, B. Edge-Padbury, S. Naberhuis-Stehouwer, and J.B. Bruss Linezolid for the treatment of complicated skin and skin structure infections in children Pediatr Infect Dis J 22 2003 S172 S177
86. E. Su, K. Crowley, J.A. Carcillo, and M.G. Michaels Linezolid and lactic acidosis: a role for lactate monitoring with long-term linezolid use in children Pediatr Infect Dis J 30 2011 804 806
87. M.W. Carroll, H. Choi, S. Min, S. Hwang, H. Park, T. Song, Y. Park, H.S. Jeon, L.C. Goldfeder, L.E. Via, J. Lebron, B. Jin, Y. Cai, C.E. Barry 3rd, and M. Lee Rhabdomyolysis in a patient treated with linezolid for extensively drug-resistant tuberculosis Clin Infect Dis 54 2012 1624 1627
88. C.R. Thomas, M. Rosenberg, V. Blythe, and W.J. Meyer III Serotonin syndrome and linezolid J Am Acad Child Adolesc Psychiatry 43 2004 790
89. M.G. Madariaga, S. Swindells, and E.E. McKee Oxazolidinones and human immunodeficiency virus Antimicrob Agents Chemother 51 2007 1130 author reply 1130
90. A.P. MacGowan Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections J Antimicrob Chemother 51 Suppl. 2 2003 ii17 ii25
91. G.L. Jungbluth, I.R. Welshman, and N.K. Hopkins Linezolid pharmacokinetics in pediatric patients: an overview Pediatr Infect Dis J 22 2003 S153 S157
92. A.K. Meagher, A. Forrest, C.R. Rayner, M.C. Birmingham, and J.J. Schentag Population pharmacokinetics of linezolid in patients treated in a compassionate-use program Antimicrob Agents Chemother 47 2003 548 553
93. H. Dong, X. Wang, Y. Dong, J. Lei, H. Li, H. You, M. Wang, J. Xing, J. Sun, and H. Zhu Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients Int J Antimicrob Agents 38 2011 296 300
94. T. Gee, R. Ellis, G. Marshall, J. Andrews, J. Ashby, and R. Wise Pharmacokinetics and tissue penetration of linezolid following multiple oral doses Antimicrob Agents Chemother 45 2001 1843 1846
95. J.E. Conte, J.A. Golden, J. Kipps, and E. Zurlinden Intrapulmonary pharmacokinetics of linezolid Antimicrob Agents Chemother 46 2002 1475 1480
96. D. Honeybourne, C. Tobin, G. Jevons, J. Andrews, and R. Wise Intrapulmonary penetration of linezolid J Antimicrob Chemother 51 2003 1431 1434
97. P. Myrianthefs, S.L. Markantonis, K. Vlachos, M. Anagnostaki, E. Boutzouka, D. Panidis, and G. Baltopoulos Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients Antimicrob Agents Chemother 50 2006 3971 3976
98. R. Yogev, B. Damle, G. Levy, and S. Nachman Pharmacokinetics and distribution of linezolid in cerebrospinal fluid in children and adolescents Pediatr Infect Dis J 29 2010 827 830
99. J.W. Alffenaar, R. van Altena, I.M. Harmelink, P. Filguera, E. Molenaar, A.M. Wessels, D. van Soolingen, J.G. Kosterink, D.R. Uges, and T.S. van der Werf Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients Clin Pharmacokinet 49 2010 559 565
100. B. McGee, R. Dietze, D.J. Hadad, L.P. Molino, E.L. Maciel, W.H. Boom, M. Palaci, J.L. Johnson, and C.A. Peloquin Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis Antimicrob Agents Chemother 53 2009 3981 3984
101. M.S. Bolhuis, R.V. Altena, D.V. Soolingen, W.C. Lange, D.R. Uges, T.S. Werf, J.G. Kosterink, and J.W. Alffenaar Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients Eur Respir J 2013
102. C.R. Rayner, A. Forrest, A.K. Meagher, M.C. Birmingham, and J.J. Schentag Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme Clin Pharmacokinet 42 2003 1411 1423
103. D. Andes, M.L. van Ogtrop, J. Peng, and W.A. Craig In vivo pharmacodynamics of a new oxazolidinone (linezolid) Antimicrob Agents Chemother 46 2002 3484 3489
104. C.D. Mitnick, B. McGee, and C.A. Peloquin Tuberculosis pharmacotherapy: strategies to optimize patient care Expert Opin Pharmacother 10 2009 381 401
105. M. Hui, C. Au-Yeang, K.T. Wong, C.Y. Chan, W.W. Yew, and C.C. Leung Post-antibiotic effects of linezolid and other agents against Mycobacterium tuberculosis Int J Antimicrob Agents 31 2008 395 396
106. World Health Organization Guidelines for the programmatic management of drug-resistant tuberculosis - 2011 update 2011 WHO Geneva, Switzerland
107. W.J. Koh, Y.R. Kang, K. Jeon, O.J. Kwon, J. Lyu, W.S. Kim, and T.S. Shim Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients J Antimicrob Chemother 67 2012 1503 1507
108. M.S. Bolhuis, R. van Altena, and J.W. Alffenaar Comment on: daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients J Antimicrob Chemother 67 2012 2055 2056 author reply 2056-2057
109. W.W. Yew, K.C. Chang, and C.H. Chau Comment on: daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis J Antimicrob Chemother 64 2009 1119 author reply 1119-1120
110. K.C. Chang, W.W. Yew, S.W. Cheung, C.C. Leung, C.M. Tam, C.H. Chau, P.K. Wen, and R.C. Chan Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis? Antimicrob Agents Chemother 57 2013 3445 3449
111. J.A. Seddon, S. Thee, K. Jacobs, A. Ebrahim, A.C. Hesseling, and H.S. Schaaf Hearing loss in children treated for multidrug-resistant tuberculosis J Infect 2012